<DOC>
	<DOCNO>NCT00252811</DOCNO>
	<brief_summary>This Phase II , randomise , double-blind , placebo-controlled study . Subjects histologically-confirmed oestrogen receptor negative ( ER- ) , progesterone receptor negative ( PgR- ) primary breast cancer breast cancer randomly assign 2:1 ratio receive ZD1839 250 mg daily match placebo total period 5 week . Surgical intervention take place 4 week ( Day 29 ) treatment continue 1 week surgery .</brief_summary>
	<brief_title>A Study ZD1839 Effects Cell Proliferation Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologicallyconfirmed ER PgR primary breast cancer Stage T .5 cm , N01 , M0 No previous treatment breast cancer ALT AST great 2.5 time ULRR Metastatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>